Heidi  Hagen net worth and biography

Heidi Hagen Biography and Net Worth

Director of ZIOPHARM Oncology
Ms. Hagen, an experienced and entrepreneurial biotechnology operations executive, joined Ziopharm’s Board in June 2019. She is Co-Founder and Advisor of Vineti, a cloud-based software platform company that addresses challenges in data management from order through cell collection, manufacturing, and delivery of personalized treatments such as cell and gene therapies and cancer vaccines. Beginning her career at Immunex Corporation, Ms. Hagen worked for ten years in a range of roles in drug development and operations management. Following Immunex, she served as Senior Vice President of Operations for more than a decade at Dendreon. More recently, she was the Global Chief Operating Officer for SOTIO, a diverse pharmaceutical company specializing in oncology, based in Prague.  Ms. Hagen also serves on the board of directors for Vericel, a commercial-stage biopharmaceutical company specializing on cellular therapies for sports medicine and severe burn care markets. She has a B.S. in Cell and Molecular Biology, an M.S. in Bioengineering, and an MBA from the University of Washington.

What is Heidi Hagen's net worth?

The estimated net worth of Heidi Hagen is at least $0.00 as of September 2nd, 2021. Ms. Hagen owns 108,333 shares of ZIOPHARM Oncology stock worth more than $0 as of November 26th. This net worth evaluation does not reflect any other investments that Ms. Hagen may own. Learn More about Heidi Hagen's net worth.

How do I contact Heidi Hagen?

The corporate mailing address for Ms. Hagen and other ZIOPHARM Oncology executives is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. ZIOPHARM Oncology can also be reached via phone at (617) 259-1970 and via email at [email protected]. Learn More on Heidi Hagen's contact information.

Has Heidi Hagen been buying or selling shares of ZIOPHARM Oncology?

Heidi Hagen has not been actively trading shares of ZIOPHARM Oncology within the last three months. Most recently, on Thursday, September 2nd, Heidi Hagen bought 23,770 shares of ZIOPHARM Oncology stock. The stock was acquired at an average cost of $1.76 per share, with a total value of $41,835.20. Following the completion of the transaction, the director now directly owns 108,333 shares of the company's stock, valued at $190,666.08. Learn More on Heidi Hagen's trading history.

Who are ZIOPHARM Oncology's active insiders?

ZIOPHARM Oncology's insider roster includes Kevin Boyle, Sr. (CEO), Eleanor de Groot (EVP), Heidi Hagen (Director), and Jaime Vieser (Director). Learn More on ZIOPHARM Oncology's active insiders.

Heidi Hagen Insider Trading History at ZIOPHARM Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2021Buy23,770$1.76$41,835.20108,333View SEC Filing Icon  
See Full Table

Heidi Hagen Buying and Selling Activity at ZIOPHARM Oncology

This chart shows Heidi Hagen's buying and selling at ZIOPHARM Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ZIOPHARM Oncology Company Overview

ZIOPHARM Oncology logo
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.08
Low: $0.82
High: $1.39

2 Week Range

Now: N/A

Volume

2,127,500 shs

Average Volume

2,008,312 shs

Market Capitalization

$187.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71